Delgocitinib Cream Dose Response in Adult Eczema: An Eight-Week Phase 2b Trial

Research interpretation for education; consult a clinician for personal treatment.

Purpose of a dose-ranging study

A randomized, double-blind, vehicle-controlled phase 2b trial evaluated multiple concentrations of delgocitinib cream in adults with mild-to-severe atopic dermatitis over eight weeks. Dose-ranging trials help identify whether greater exposure produces greater clinical response and which dose should advance.

What dose response can—and cannot—show

A consistent relationship across concentrations strengthens evidence that the active drug contributes beyond the vehicle. It does not by itself establish the best real-world dose, because tolerability, treated body surface area, application frequency and long-term exposure also matter.

Vehicle response is clinically meaningful

Vehicle creams can hydrate the stratum corneum, reduce friction and improve symptoms. High vehicle response does not invalidate a trial; it shows why active-versus-vehicle difference is more informative than change from baseline alone. Comparing this trial with another topical study requires caution because severity, age, rescue therapy and outcome timing differ.

Short-term safety boundaries

Eight weeks can identify common local reactions but not every rare or delayed event. Delgocitinib is a topical Janus kinase inhibitor, and regulatory authorization differs by formulation, condition and country. Patients should not substitute compounded or imported products for an approved prescription.

Infants are not small adults

Adult phase 2b results do not establish safety for babies or young children. Infant skin has a higher surface-area-to-weight relationship, and diaper occlusion can alter absorption. Pediatric use requires age-specific labeling and clinician direction.

Bottom line

The trial supports a pharmacologic dose-response signal for the tested cream. Phase 3, longer-term and active-comparator evidence is needed for complete treatment positioning.

Related research articles

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Delgocitinib cream phase 2b trial
2. AAD systemic and phototherapy guideline
3. AAD topical therapy guideline
4. AAAAI/ACAAI GRADE guideline
5. Peer-led online self-management randomized trial
6. Emollient plus versus urea 10% trial
7. Upadacitinib in adults aged 60 years or older
8. Lebrikizumab in older adults real-world study
9. Tralokinumab in adults aged 70 years or older
10. Abrocitinib in elderly adults real-world study
11. JAK inhibitors in adults with cardiovascular comorbidity
12. Ruxolitinib after topical treatment failure trial
13. Mometasone, crisaborole and tofacitinib pilot
14. CAN UpTIMISE after dupilumab study
15. DLLIM international 15,450-patient study
16. REZOLVE-AD phase 2b trial
17. Model-based meta-analysis of 77 studies
18. Targeted-therapy tapering systematic review
19. IL-4 receptor inhibitor meta-analysis
20. Dupilumab SOLO phase 3 trials
21. Tralokinumab ECZTRA 1 and 2 trials
22. Lebrikizumab ADvocate trials
23. Upadacitinib Measure Up trials
24. Abrocitinib JADE MONO-1 trial

No cited source endorses Dr. Arsy products.